Trial Profile
A Phase I Single Patient IND for PD-0325901
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Mirdametinib (Primary)
- Indications Solid tumours
- Focus Expanded access; Therapeutic Use
- 27 Nov 2014 New trial record